Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?

Philip A. Powell
DOI: https://doi.org/10.1080/14737167.2024.2334349
2024-03-26
Expert Review of Pharmacoeconomics & Outcomes Research
Abstract:KEYWORDS: Health state valuation (e.g. calculating numerical values representing people's relative preference for living in particular health states) is an essential ingredient for health technology assessment (HTA). It allows for the generation of utilities to calculate health-related quality of life outcomes and adds the 'QA' to the QALY, or quality-adjusted life year [ Citation 1 ]. For HTA, valuing health states uses standardized methodologies, such as time trade-off (TTO) or discrete choice experiment (DCE) with duration, with a targeted sample of people to derive their preference (or utility) weights for living in particular states of health relative to preference for survival or life expectancy. The sample used for valuing health states differs depending on locality and HTA body, but in the UK a sample of the adult (taxpaying) public is recruited, representative on key demographic criteria, such as age, sex, ethnicity, and socioeconomic status [ Citation 2 ].
pharmacology & pharmacy,health care sciences & services,health policy & services
What problem does this paper attempt to address?